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1 
2 
3 Abstract 
4 
5 
6 
Aims:  Cardiovascular disease is  a leading  cause of morbidity and  mortality.     Smooth 
8 
9 muscle cells (SMC) comprising the vascular wall can switch phenotypes from contractile 
10 
11 to synthetic, which can promote the development of aberrant remodelling and intimal 
12 
13 
hyperplasia (IH). MicroRNA-21 (miR-21) is a short, non-coding RNA that has been 
14 
15 
16 implicated  in  cardiovascular  diseases  including  proliferative  vascular   disease      and 
17 
18 ischaemic  heart  disease.  However,  its  involvement  in  the  complex  development   of 
19 
20 
atherosclerosis has yet to be ascertained. 
21 
22 
23 
24 Methods: Smooth muscle cells (SMC) were isolated from human saphenous veins   (SV). 
25 
26 miR-21 was over-expressed and the impact of this on morphology, proliferation, gene 
27 
28 and protein expression related to synthetic SMC phenotypes monitored. 
29 
30 
31 
Results:  Over-expression  of  miR-21  increased  the  spread  cell  area  and  proliferative 
33 
34 capacity  of  SV-SMC  and  expression  of  MMP-1,  whilst  reducing  RECK       protein, 
35 
36 indicating a switch to the synthetic phenotype. Furthermore, PDGF-BB (a growth   factor 
37 
38 
implicated in vasculoproliferative conditions) was able to induce miR-21 expression   via 
39 
40 
41 the PI3K and ERK signalling pathways. 
42 
43 
44 Conclusion: This study has revealed a mechanism whereby PDGF-BB induces expression 
45 
46 
of miR-21 in SV-SMC, subsequently driving conversion to a synthetic SMC   phenotype, 
47 
48 
49 propagating the  development  of  IH.  Thus,  these  signaling pathways  may be attractive 
50 
51 therapeutic targets to minimise progression of the disease. 
52 
53 
54 Keywords: 
55 
56 
57 
58 
59 
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1 
2 
3 Introduction 
4 
5 
6 
Despite  continued  advances  in  knowledge  and  therapeutic  strategies,  atherosclerosis 
8 
9 remains  the  leading  cause  of  cardiovascular  disease  (CVD)  around  the  world     [1]. 
10 
11 Atherosclerosis   is   a   chronic,   progressive   inflammatory   disorder   which   involves 
12 
13 
interactions  of  different  vascular  cell  types  that  are  the  underlying  cause  of angina, 
14 
15 
16 coronary artery disease (CAD) and stroke [2]. Atherosclerosis in the coronary arteries can 
17 
18 block the blood supply to the heart tissue, causing myocardial infarction and necessitating 
19 
20 
vascular reconstruction. 
21 
22 
23 
24 The advent of percutaneous coronary intervention (PCI) has improved treatment   options 
25 
26 for  patients,  yet  coronary  artery  bypass  grafting  (CABG)  remains  the  mainstay  for 
27 
28 patients with multivessel disease and impaired ejection fraction [3]. The commonly  used 
29 
30 
bypass conduits for CABG are the autologous internal mammary artery (IMA) and the 
32 
33 saphenous vein (SV), with the SV graft remaining popular for multiple grafts due to its 
34 
35 ease of harvesting and ready availability. However, during the first year post-CABG up 
36 
37 
to 15% of  SV  grafts fail with an  expected 4-5% attrition rate each  year thereafter    [4]. 
38 
39 
40 Therefore, in 10 years SV graft failure rates are close to 50% and approximately 31%   of 
41 
42 all CABG surgeries in the United Kingdom necessitate re-intervention [5]. Conversely, 
43 
44 
80-95 % of IMA grafts remain patent at 10 years [6]. 
45 
46 
47 
48 The underlying pathological lesion of SV graft stenosis is the characteristic  development 
49 
50 of intimal hyperplasia (IH). IH can be detected approximately 4-6 weeks following SV 
51 
52 grafting  [7]  and  this  can  be  further  augmented  by  continued  atherosclerotic   lesion 
53 
54 
development in the vein graft within one year following vein implantation [8]. 
56 
57 
58 
59 
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1 
2 
3 Smooth muscle cells (SMC) constitute the major cell type in the blood vessel wall, and 
4 
5 
their principal role is to maintain vascular tone and vessel homeostasis. In health, SMC 
7 
8 exist in a contractile, differentiated state with a low turnover rate, but following injury 
9 
10 and in response to  circulating cytokines  and  growth factors, they switch  to a   synthetic 
11 
12 
phenotype  that  is  characterised  by  increased  proliferation,  loss  of  contractility,   and 
13 
14 
15 secretion of extracellular matrix degrading enzymes. This encourages migration of  SMC 
16 
17 into  the  intimal  layer  of  the  blood  vessel,  thus  initiating  a  remodelling  event  as an 
18 
19 
adaptive response that ultimately can exacerbate the development of intimal   hyperplasia 
20 
21 
22 and restenosis [9]. 
23 
24 
25 Platelet-derived   growth   factor   BB   (PDGF-BB)   is   a   potent   SMC   mitogen   and 
26 
27 chemoattractant  that  induces  cellular  dedifferentiation  into  a  synthetic      phenotype, 
28 
29 
increasing proliferation and migration into the intima such as is evident in atherosclerosis 
31 
32 and restenosis [10, 11]. In addition to being secreted from platelets, PDGF is secreted  by 
33 
34 endothelial cells (EC) and SMC [12]. PDGF-BB-induced SMC dedifferentiation is driven 
35 
36 
through   the   phosphoinositide-3-kinase/AKT   and   mitogen-activated   protein   kinase 
37 
38 
39 extracellular regulated kinase 1/2 (ERK1/2) intracellular transduction pathways [13].   As 
40 
41 increased SMC migration and proliferation constitute the cornerstone of IH and SV  graft 
42 
43 
failure, PDGF-BB is implicated in its progression [14]. 
44 
45 
46 
47 MicroRNAs   (miRs)   are   short,   non-coding   RNAs   that   negatively   regulate   gene 
48 
49 expression.  Emerging  evidence  reveals  miR-21  to  be  one  of  the  most  dysregulated 
50 
51 miRNAs in the cardiovascular system. miR-21 is expressed in most cardiovascular cell 
52 
53 
types  including vascular  SMC  [15]  and  can  mediate the pathological  development of 
55 
56 neointimal  hyperplasia [15],  atherosclerotic lesions  [16], and  cardiac hypertrophy   and 
57 
58 
59 
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1 
2 
3 fibrosis   [17,   18].   Indeed,   miR-21   expression   is   reportedly   elevated   in    human 
4 
5 
atherosclerotic plaques [19] and is consistently increased in neointimal lesions  following 
7 
8 either grafting or stent implantation in murine and porcine models [20, 21].  Furthermore, 
9 
10 miR-21 is increased in human coronary artery following stenting [20] and in ex vivo 
11 
12 
human SV models of neointimal hyperplasia [21]. Thus, examining the molecular and 
13 
14 
15 cellular effects of elevated miR-21 in human SMC is of critical importance. 
16 
17 
18 Despite advances in modern therapies, vein graft failure is still a significant problem  that 
19 
20 
requires identification of novel targets for development of new therapeutics to ameliorate 
21 
22 
23 adverse vascular remodelling. Thus, the aim of this study was to explore a relationship 
24 
25 between miR-21 and PDGF in the cellular mechanisms underlying SV-SMC  dysfunction 
26 
27 that occurs in vein graft failure. 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
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1 
2 
3 Experimental procedures 
4 
5 
6 
7 Cell culture 
8 
9 
10 Human SV specimens were obtained from patients undergoing elective CABG surgery at 
11 
12 the  Leeds  General  Infirmary.  Local  ethical  committee  and  informed,  written patient 
13 
14 
consent was obtained and the study conformed to the Declaration of Helsinki.    SV-SMC 
15 
16 
17 were  cultured  using  an  explant  technique  as  previously described  [22].  Briefly, vein 
18 
19 segments were cleaned of adventitia, opened longitudinally and denuded of endothelium. 
20 
21 
Tissue was chopped finely into ~1mm
3  
fragments and maintained in medium   containing 
22 
23 
24 10% foetal bovine serum in T25 flasks. Once confluent, explanted SMC were serially 
25 
26 passaged in a 1:3 ratio. All experiments were performed on low passage (3-5) cells. As 
27 
28 we  have  previously  demonstrated  profound  phenotypic  changes  in  SV-SMC isolated 
29 
30 
from patients with Type 2 diabetes [23-25], all experiments were performed using cells 
32 
33 cultured from patients without a diagnosis of diabetes. 
34 
35 
36 miR-21 transfection 
37 
38 
39 
Subconfluent   SV-SMC   were   transfected   with   30   nM   premiR-21 (hsa-miR21-5p; 
40 
41 
42 AM17100) or its associated negative control (AM17110; “premiR-ve”) using 
43 
44 Lipofectamine 2000 (all Life Technologies, Paisley, UK). Cells were harvested after 72 h 
45 
46 
and  endpoints  determined  (cell  morphology,  F-actin  staining,  RNA  isolation)        or 
47 
48 
49 proliferation assays performed. 
50 
51 
52 Cell morphology 
53 
54 
55 
56 
57 
58 
59 
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1 
2 
3 Images  of  sub-confluent  cells  were  captured   under  the  light  microscope  at      x100 
4 
5 
magnification. For each patient population, 50 randomly selected cells were measured by 
7 
8 tracing   the   cell   boundaries   and   areas   were   calculated   using   ImageJ     software 
9 
10 (https://imagej.nih.gov/ij/) [26]. For cytoskeletal assessment, cells were cultured on glass 
11 
12 
coverslips  in  medium  containing  0.4%  foetal  calf  serum  (minimal  growth  medium, 
13 
14 
15 MGM) for 72h. After fixation in 4% paraformaldehyde, F-actin fibres were labelled using 
16 
17 rhodamine  phalloidin  (1:40)  as  previously  described  [27].  Fluorescence  images were 
18 
19 
captured using an LSM510 upright confocal microscope at x200 magnification. 
20 
21 
22 
23 Cell proliferation 
24 
25 
26 SV-SMC proliferation was determined by in vitro counting of live cells in triplicate using 
27 
28 trypan blue and a haemocytometer as we described previously [23]. 
29 
30 
31 
32 Quantitative real-time RT-PCR 
33 
34 
35 For quantification of miR-21 expression, cellular RNA was used to produce cDNA using 
36 
37 TaqMan  MicroRNA  Reverse  Transcription  System.  MiR-21  expression  levels   were 
38 
39 
measured using miR-21 TaqMan microRNA assay (Applied Biosystems) and real-time 
40 
41 
42 PCR performed according to manufacturer’s protocols. Data were analysed using the 
43 
44 comparative CT method and values normalised to U6 expression. For gene expression 
45 
46 
studies, cellular RNA was extracted and real-time RT-PCR was performed in triplicate 
47 
48 
49 using Applied Biosystems 7500 PCR system and intron-spanning human collagen type  1 
50 
51 (COL1A1;  Hs00164004_m1),  matrix  metalloproteinase-1  (MMP1;   Hs00233958_m1), 
52 
53 interleukin  1-alpha  (IL1α;  Hs00174092_m1),  reversion  inducing cysteine  rich protein 
54 
55 
with  Kazal  motifs  (RECK;  Hs01019179_m1)  primers  and  TaqMan  probes.  Data are 
57 
58 
59 
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1 
2 
3 expressed   as   percentage   of   glyceraldehyde-3-phosphate   dehydrogenase   (GAPDH) 
4 
5 
endogenous  control  levels  (Hs99999905_m1)  using  the  formula  2
-∆CT   
x  100  or  to a 
7 
8 control sample using the formula 2
-∆∆CT
. 
9 
10 
11 ProMMP-1 ELISA 
12 
13 
14 
SV-SMC from five different patients were transfected with 30 nM premiR-21 or premiR- 
15 
16 
17 ve prior to being stimulated with 10 ng/ml PDGF-BB for 24 h. Conditioned medium  was 
18 
19 collected from the cells and proMMP-1 measured using a human proMMP-1  Quantikine 
20 
21 
ELISA kit (R&D Systems, DMP100). Data are expressed relative to proMMP-1 levels in 
22 
23 
24 cells cultured with Lipofectamine 2000 reagent only. 
25 
26 
27 Atherosclerosis microarray 
28 
29 
30 SV-SMC  from  four  different  patients  were  transfected  with  30  nM  premiR-21     or 
31 
32 
equivalent premiR-ve. Cellular RNA was extracted and reverse transcribed.    Expression 
34 
35 levels of 84 atherosclerosis-related genes were quantified using a focused SYBR    green- 
36 
37 based  real-time  PCR  array  (RT2  Profiler  Human  Atherosclerosis,  SABiosciences    / 
38 
39 
Qiagen  PAHS-038ZA-12)  and  the  Applied  Biosystems  7500  Real-time  PCR system. 
40 
41 
42 ∆CT  vales  for  the  target  genes  were  calculated  by  subtracting  the  mean  CT  value 
43 
44 (threshold cycle number) of the 5 housekeeping genes on the array from the CT value   of 
45 
46 
the target genes. Data are expressed as relative quantification (RQ) values compared with 
47 
48 
the 5 housekeeping genes using the formula RQ=2
-∆CT
. 
50 
51 
52 Immunoblotting 
53 
54 
55 
56 
57 
58 
59 
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1 
2 
3 Immunoblotting was performed essentially as per our previous protocol [28]. Whole  cell 
4 
5 
homogenates   were   prepared   and   protein   was   separated   using   SDS-PAGE   10% 
7 
8 polyacrylamide gels and transferred to PVDF membranes. Phosphorylation of AKT   and 
9 
10 ERK1/2 was determined by   immunoblotting   with phospho-specific monoclonal 
11 
12 
antibodies (#9106 mouse, #4060 rabbit respectively). Membranes were  re-probed    with 
13 
14 
15 AKT and ERK expression antibodies (#2920 and #4695 respectively, all Cell Signaling 
16 
17 Technology). For RECK protein, a 7.5% SDS-PAGE gel was prepared and α-tubulin 
18 
19 
used as a loading control. 
20 
21 
22 
23 Statistical Analysis 
24 
25 
26 All results are expressed as a mean ± SEM. Statistical analysis was performed using 
27 
28 GraphPad   Prism   7   by   one-way   ANOVA   followed   by   Newman-Keuls   multiple 
29 
30 
comparisons post-hoc test. Paired ratio t-tests were performed on log transforms of all 
32 
33 normalised data to  test  statistical significance  where  appropriate. Correlation   between 
34 
35 miR-21  and  COL1A1  gene  expression  was  assessed  using  Pearson’s       correlation, 
36 
37 
indicated by R
2
. P < 0.05 was considered statistically significant. 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
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1 
2 
3 Results 
4 
5 
6 
7 Over-expressing miR-21 induces phenotypic and functional changes in SV-SMC 
8 
9 
10 Cells over-expressing miR-21 exhibited an enlarged, rhomboid morphology which was 
11 
12 visible under phase contrast  microscopy (Fig.  1A),  accounting for  a 1.7-fold  increased 
13 
14 
spread  area  relative  to  control  premiR-ve  transfected  cells  (Fig.  1B).  This  enlarged 
15 
16 
17 morphology was further emphasised by rhodamine phalloidin fluorescence   microscopy, 
18 
19 which   revealed   that   the   F-actin   cytoskeleton   appeared   visually   intact   in   these 
20 
21 
morphologically aberrant SMC (Fig. 1C). Cells over-expressing miR-21 also exhibited 
22 
23 
24 increased cell proliferation, resulting in a 1.8-fold increase in cell number relative to 
25 
26 control premiR-ve cells after 4 days (Fig. 1D). Collagen type 1 is known to be   increased 
27 
28 in  synthetic SMC  [29]  and  accordingly,  we discovered  that  miR-21  was significantly 
29 
30 
positively correlated with COL1A1 mRNA expression (Fig. 1E). 
32 
33 
34 Microarray identification  of  MMP1 and  IL1A  as miR-21-regulated  genes in    SV- 
35 
36 SMC 
37 
38 
39 
Using  SMC  over-expressing  miR-21,  we  performed  a  focused  microarray to explore 
40 
41 
42 expression  of  84  potential  target  genes  related  to  atherosclerosis  and cardiovascular 
43 
44 disease. The pattern of gene expression induced by miR-21 over-expression is   presented 
45 
46 
in a volcano scatter plot (Fig. 2A). Of the 84 genes studied, 10 genes presented a fold 
47 
48 
49 change  ≥   ±   1.5.   MMP1,   MMP3,   interleukin   1   receptor  2   (IL1R2),  peroxisome 
50 
51 proliferator-activator  receptor  gamma  (PPARG)  and  integrin  subunit  beta  2 (ITGB2) 
52 
53 displayed  ≥  1.5-fold  increase  in  the  premiR-21  transfected  cells  relative  to   control 
54 
55 
56 premiR-ve transfected SV-SMC. Conversely, interleukin-1(IL1A), kinase insert domain 
57 
58 
59 
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1 
2 
3 receptor (KDR), Baculoviral IAP repeat containing 3 (BIRC3), von Willibrand factor 
4 
5 
(VWF) and interleukin 5 (IL5) showed > 1.5-fold decrease in the premiR-21 transfected 
7 
8 cells relative to premiR-ve controls (Table 1). 
9 
10 
11 Genes  identified  by  microarray  were  subsequently  validated  using  specific  TaqMan 
12 
13 
probes and RT-PCR using RNA from six different patients, which included the four 
14 
15 
16 original samples that were analysed by array. In this series of experiments, we confirmed 
17 
18 a  statistically  significant  increase  in  MMP1  mRNA  expression  in  the       premiR-21 
19 
20 
transfected cells versus premiR-ve controls (Fig. 2B), which was associated with a ~40% 
21 
22 
23 increase in proMMP-1 secretion (Fig. 2C). On the contrary, we were unable to validate 
24 
25 the  IL1A  data  where  only  a  small  but  non-significant  reduction  was  evident  in  the 
26 
27 premiR-21 transfected cells relative to the premiR-ve SV-SMC (Fig. 2D). 
28 
29 
30 
31 miR-21 over-expression downregulates RECK in SV-SMC 
32 
33 
34 RECK is a recognised target of miR-21 that is known to be involved in cell  proliferation 
35 
36 [30]. In our study, miR-21 over-expression in SV-SMC for 72h led to ~50% reduction  in 
37 
38 
RECK mRNA expression levels (Fig. 2E), yet there were no detectable changes in RECK 
39 
40 
41 protein levels at this time point (data not shown). Extended study revealed a ~40% 
42 
43 reduction in RECK protein levels in response to premiR-21 transfection after 8 days (Fig. 
44 
45 
2F). 
46 
47 
48 
49 PDGF-BB  increases  miR-21  expression  via  AKT  and  ERK1/2  pathways  in SV- 
50 
51 SMC: 
52 
53 
54 
55 
56 
57 
58 
59 
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1 
2 
3 To  identify the potential  source  of miR-21  up-regulation  in  SV-SMC  we treated cells 
4 
5 
with the potent chemoattractant and mitogen PDGF-BB which is known to be   increased 
7 
8 in proliferative vascular disorders [31]. Exposure of SV-SMC for 24 h to  physiologically 
9 
10 relevant (1 ng/ml and 10 ng/ml; [32, 33]) concentrations of PDGF stimulated miR-21 
11 
12 
expression; an effect that was maintained up to 72 h (Fig. 3A). 
13 
14 
15 
16 Binding of PDGF to its cognate receptor results in a signalling cascade that induces 
17 
18 phosphorylation of both AKT and ERK1/2 [34]. To determine which of these pathways 
19 
20 
was  involved  in  inducing  miR-21  expression,  we  used  specific        pharmacological 
21 
22 
23 inhibitors. PDGF-BB treatment induced phosphorylation of both AKT and ERK1/2 as 
24 
25 expected  and  pathway-specific  phosphorylation  events  were  inhibited  by pre-treating 
26 
27 with  inhibitors  of  AKT  (LY294002)  and  ERK1/2  (PD98059)  pathways  (Fig.     3B). 
28 
29 
Inhibiting either pathway independently was able to completely abrogate the induction of 
31 
32 miR-21 expression by PDGF-BB, confirming the requirement for both pathways in  miR- 
33 
34 21 regulation in these cells (Fig. 3C). 
35 
36 
37 
PDGF-BB  mimics  the  effect  of  miR-21  over-expression  on  MMP-1  and  RECK 
38 
39 
40 expression 
41 
42 
43 Having shown that PDGF-BB increased miR-21 expression (Fig. 3), and that miR-21 
44 
45 
overexpression led to an increase in MMP1 mRNA expression and inhibition of RECK 
46 
47 
48 expression (Fig. 2), we proceeded to seek evidence for a link between PDGF and these 
49 
50 targets.  PDGF-BB  significantly  induced  MMP1  mRNA  at  24  h  in  a  concentration- 
51 
52 dependent  manner, although this effect  was transient  and expression levels returned   to 
53 
54 
baseline by 72 h (Fig. 3D). In parallel, RECK mRNA was significantly downregulated  in 
56 
57 
58 
59 
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1 
2 
3 a concentration-dependent manner, and this effect was maintained over the full 72 h 
4 
5 
period of study (Fig. 3E). 
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28 
29 
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31 
32 
33 
34 
35 
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37 
38 
39 
40 
41 
42 
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1 
2 
3 Discussion 
4 
5 
6 
Dysregulation of SMC differentiation is an event critical to the development of CVD. 
8 
9 The presence of characteristically dedifferentiated SMC in IH is well recognised and thus 
10 
11 investigations  into  the  mechanisms  contributing  to  this  phenotypic  reversion  are  of 
12 
13 
significant clinical importance. Two of the predominant mechanisms for SV graft  failure 
14 
15 
16 are IH and accelerated atherosclerosis. In the present study, we utilised clinically relevant 
17 
18 human SV-SMC and revealed signalling pathways whereby overexpression of miR-21 
19 
20 
led to acquisition of a synthetic phenotype. 
21 
22 
23 
24 miR-21 as a driver of synthetic SMC phenotypes 
25 
26 
27 The  importance  of  miR-21  in  the  cardiovascular  system  is  well  recognised.  It      is 
28 
29 aberrantly expressed in vascular SMC [15] and EC [35] following vascular injury, and  is 
30 
31 
significantly  up-regulated  in  human  atherosclerotic  plaques  [19],  injured  rat   carotid 
33 
34 arteries  [15],  following stent  implantation  or  vascular  grafting in  murine  and porcine 
35 
36 models, and in human ex vivo SV cultures [20, 21]. However, its influence on human SV- 
37 
38 
SMC remodelling following bypass grafting is unknown. In this study we used an over- 
39 
40 
41 expression approach to determine the impact of miR-21 on SMC phenotype and  function 
42 
43 in vitro. 
44 
45 
46 
Synthetic SMC in remodelling vessels are known to adopt a rhomboid morphology, 
47 
48 
49 secrete high levels of collagen type 1 and have a high turnover rate [29, 36]. All of   these 
50 
51 features were observed in miR-21 over-expressing SV-SMC, supporting the notion that 
52 
53 miR-21 was driving the dedifferentiation. Given the widespread reporting of miR-21 as a 
54 
55 
proto-oncogene that increases proliferation in a number of pathological models including 
57 
58 
59 
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1 
2 
3 vascular SMC [15, 37, 38], its impact specifically on SV-SMC is perhaps unsurprising. In 
4 
5 
direct contrast however,  miR-21 has been purported to drive a differentiated,  contractile 
7 
8 phenotype  in  human  pulmonary  artery  SMC  [39]  and  correlates  with  expression  of 
9 
10 smooth  muscle  differentiation  genes  [40].  Given  this  disparity,  we  perceived  it was 
11 
12 
important to validate this hypothesis in clinically relevant human SV-SMC. Our   present 
13 
14 
15 data highlight the species- and cell type-specific nature of miR-21’s mechanism of action. 
16 
17 
18 Identification of downstream miR-21 targets that contribute to vascular remodelling 
19 
20 
21 
As miR-21 over-expressing cells were dedifferentiated, and such SMC are common in 
22 
23 
24 IH, we proceeded to use a microarray-based approach to identify downstream targets    of 
25 
26 miR-21 in SV-SMC that may contribute to the development of CVD. IL1A is a pro- 
27 
28 inflammatory cytokine that is elevated in atherosclerosis [41], however its regulation   by 
29 
30 
miR-21 could not be corroborated in SV-SMC. In contrast, the array data for MMP1  was 
32 
33 validated using specific Taqman assays which identified MMP1 as being regulated by 
34 
35 miR-21 in these cells. Protein levels of proMMP-1 secreted from premiR-21   transfected 
36 
37 
cells  exhibited  an  approximate  40%  increase.  Whilst  this  did  not  achieve statistical 
38 
39 
40 significance, a possible explanation may be that we collected conditioned media at too 
41 
42 early a time point (24h). The scenario could well be similar to that we discovered with 
43 
44 
respect  to  RECK  mRNA  expression  changes  and  subsequent  modulation  of  protein 
45 
46 
47 levels. An extended time course of MMP-1 secretion would prove useful in this respect. 
48 
49 
50 MMPs  play  an  important  role  in  degrading  the  ECM  and  can  contribute  to  matrix 
51 
52 destabilisation [42]. Furthermore, digestion of integrins by MMPs can facilitate SMC 
53 
54 
dedifferentiation  [43].  Interestingly,  in  SV-SMC,  there  was  a  positive     relationship 
56 
57 
58 
59 
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1 
2 
3 between miR-21 and MMP1 mRNA expression. Normally, miRs negatively regulate   the 
4 
5 
expression of direct gene targets [44]. This suggests that the relationship between miR-21 
7 
8 and MMP1 in SV-SMCs is complex and involves an intermediary step whereby the target 
9 
10 of miR-21 firstly inhibits expression of a gene that normally acts as a repressor of MMP1 
11 
12 
expression. 
13 
14 
15 
16 Transcriptional regulation of MMPs is complicated, encompassing multiple  intracellular 
17 
18 signalling pathways and transcription factors [45]. RECK is a membrane-bound MMP 
19 
20 
inhibitor that has been reported to regulate the gelatinases MMP-2 and -9, and their 
21 
22 
23 activator membrane type  1-MMP  (MT1-MMP) [46]. Previous studies have shown   that 
24 
25 miR-21 overexpression in various cancer cell lines reduces mRNA and protein levels   of 
26 
27 RECK [47]. Furthermore, in vascular SMC, knockdown of RECK led to increased MMP- 
28 
29 
2 and -9 expression, and an increase in cell proliferation [48]. In the present study, 
31 
32 transfection with premiR-21 inhibited RECK mRNA expression after 3 days, and  RECK 
33 
34 protein levels after 8 days. Evidence of a direct effect of RECK on MMP-1 expression 
35 
36 
remains elusive, thus the relationship in SV-SMC is worthy of further investigation.  The 
37 
38 
39 ability to reverse PDGF-induced SV-SMC gene expression and function by   anti-miR-21 
40 
41 knockdown may also shed further light on these molecular pathways. 
42 
43 
44 
PDGF-BB is an important regulator of SMC function via miR-21 
45 
46 
47 
48 On the basis of the above evidence, elevated miR-21 expression can cause vascular SMC 
49 
50 dysfunction leading to dedifferentiation, enhanced proliferation and degradation of the 
51 
52 ECM.  MiR-21  is  known  to  be  elevated  in  proliferative  SMC  present  in  IH       and 
53 
54 
55 
56 
57 
58 
59 
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1 
2 
3 atherosclerotic plaques, thus identifying the factor(s) responsible for this elevation is of 
4 
5 
clinical relevance. 
7 
8 
9 PDGF-BB  is  a  potent  SMC  chemoattractant  and  mitogen,  which  can  promote SMC 
10 
11 dedifferentiation and proliferation [10, 11] and is elevated following vascular injury   and 
12 
13 
angioplasty [31]. PDGF-BB is purported to regulate miR-21 in a number of cell types, 
14 
15 
16 including rat aortic SMC [49]. Our observations of a modest yet consistent  up-regulation 
17 
18 of miR-21 by PDGF-BB in SV-SMC that persists over time aligns with this. However,  a 
19 
20 
recent study raised the possibility of a more complex relationship whereby miR-21 could 
21 
22 
23 prevent  the  mitogenic   effects  of  PDGF  [38].  Further  experiments  examining     any 
24 
25 attenuation  of  PDGF-BB  signalling through  over-expressing miR-21  may answer  this 
26 
27 question. 
28 
29 
30 
Both the PI3K/AKT and ERK1/2 pathways are activated upon binding of PDGF-BB to 
32 
33 its receptor, leading to SMC dedifferentiation [13, 34]. In our study, inhibition of either 
34 
35 pathway was sufficient to completely ablate miR-21 expression by PDGF-BB, indicating 
36 
37 
that  both  pathways  are  required.  Interestingly,  miR-21  itself  can  stimulate  the AKT 
38 
39 
40 pathway (via suppression of PTEN; [15, 37]) and the ERK pathway [50] potentially 
41 
42 causing  a  positive  feedback  loop  that  reinforces  the  effect  of  PDGF-BB  on miR-21 
43 
44 
expression. 
45 
46 
47 
48 Treatment of SV-SMC with PDGF-BB was sufficient to increase expression of MMP1 
49 
50 mRNA and reduce expression of RECK. Reports of a relationship between PDGF-BB 
51 
52 and RECK in the literature are lacking, although one study demonstrated that loss of 
53 
54 
RECK in fibroblasts caused a disordered chemotactic response to PDGF [51]. To our 
56 
57 
58 
59 
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1 
2 
3 knowledge, ours is the first report of PDGF-BB regulating RECK expression in human 
4 
5 
SMC  via  up-regulation  of  miR-21.  The  relationship  between  PDGF  and  MMP-1  is 
7 
8 however, better recognised and previous studies have reported a positive relationship 
9 
10 between  PDGF  and  MMP-1  [52].  Our  data  concur  with  these  findings,  and further 
11 
12 
suggest a mechanism mediated via miR-21. 
13 
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1 
2 
3 Conclusion 
4 
5 
6 
During pathological vascular remodelling, secretion of cytokines and growth factors from 
8 
9 multiple vascular cell  types are increased. Here,  we have demonstrated  how one     such 
10 
11 growth factor, PDGF-BB, controls SV-SMC phenotype, at least in part, through  miR-21. 
12 
13 
This has downstream effects on RECK and MMP-1 expression and leads to SV-SMC 
14 
15 
16 dedifferentiation (see Fig. 4 for summary diagram). Targeted inhibition of PDGF-BB 
17 
18 signalling  may  be  a  beneficial  therapeutic  strategy  following  coronary  artery bypass 
19 
20 
grafting to limit post-graft development of neointimal hyperplasia. 
21 
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Figure Legends 
17 
18 
19 
20 Figure   1:   Overexpression   of   miR-21   alters   SMC   phenotype.   SV-SMC  were 
21 
22 transfected with 30nM premiR-21 and cultured for 72h. (A) Representative images of 
23 
24 transfected SV-SMC and (B) quantification of spread cell area (n=7, **P<0.01). (C) 
25 
26 
27 Representative images of the F-actin cytoskeleton stained with rhodamine phalloidin. (D) 
28 
29 After the 72h period, cells were placed in proliferation assays and direct cell counts taken 
30 
31 after 4 days. Data is presented as a fold increase in cell number from day 0 (n=5, 
32 
33 
**P<0.01). (E) Expression of COL1A1 mRNA was positively correlated with miR-21 
35 
36 expression levels (**P=0.002, n=8). 
37 
38 
39 Figure 2: miR-21 over-expression alters atherosclerosis-related gene expression. (A) 
40 
41 
Volcano  plot  of  the  RT2  Profiler  Human  Atherosclerosis  PCR  Microarray data. The 
42 
43 
44 difference in expression level (log 2 scale) is indicated on the x-axis and the y-axis 
45 
46 indicates  statistical  significance  (-log  10  scale).  Values  located  above  the horizontal 
47 
48 
dotted line indicate P < 0.05. Only genes that had   ±1.5-fold changes are labelled; 
49 
50 
51 genes upregulated by miR-21 over-expression are indicated in grey and those down- 
52 
53 regulated are indicated in black (n=4). The array data were validated using (B) TaqMan 
54 
55 
intron-spanning  primers  for  MMP1  (n=6)  and  (C)  expression  of  proMMP-1       was 
56 
57 
58 
59 
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1 
2 
3 measured by ELISA (n=5). (D) Array data was also examined using TaqMan intron- 
4 
5 
spanning  primers  for  IL1A  (n=6).  (E)  Quantification  of  RECK  mRNA  in SV-SMC 
7 
8 transfected with premiR-21 (or premiR-ve) for 72 h (n=8). (F) Quantification of RECK 
9 
10 protein in transfected cells after 8 days (n=5). Image shows representative immunoblot 
11 
12 
with -tubulin as a loading control. ***P<0.001, **P<0.01, *P<0.05, ns=not significant. 
14 
15 
16 Figure  3:  PDGF induces  miR-21  expression  via  AKT  and  ERK1/2, and  inhibits 
17 
18 MMP-1  and  RECK1.  (A)  SV-SMC  were  treated  with  increasing  concentrations of 
19 
20 
PDGF and miR-21 expression quantified after 24-72h (n=5, **P<0.01, *P<0.05,   ns=not 
22 
23 significant. (B) SV-SMC were treated with the PI3K inhibitor LY294002 (LY; 10µM) 
24 
25 and ERK1/2 inhibitor PD98059 (PD; 30µM) for 1 h prior to PDGF stimulation (20  min). 
26 
27 
V refers to vehicle control. Representative Western blot demonstrating the efficacy of the 
28 
29 
30 inhibitors. (C) SV-SMC were treated with V, LY or PD for 1 h prior to the addition of 
31 
32 PDGF. miR-21 expression was monitored 48 h later (n=5, *P<0.05). SV-SMC were 
33 
34 treated with increasing concentrations of PDGF and the expression of (D) MMP-1 and 
35 
36 
37 (E)  RECK  quantified  after  24-72h  (n=5,  ***P<0.001,  **P<0.01,  *P<0.05,     ns=not 
38 
39 significant). 
40 
41 
42 Figure  4:  PDGF  -  miR-21  axis  in  SV-SMC.  PDGF-BB  in  the  circulation  signals 
43 
44 
through both AKT and ERK to up-regulate expression of miR-21. In turn, this inhibits 
46 
47 MMP-1 and RECK1, and drives a phenotypic switch towards a synthetic SMC such as 
48 
49 the type prevalent in atherosclerosis and neointimal hyperplasia. 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
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1 
2 
3 Table  1:  Genes  modulated  by  miR-21  overexpression  in  the  Human   Atherosclerosis 
4 
5 Microarray 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 Cells over-expressed miR-21 or the negative control, and RNA was subsequently analysed 
47 
48 
using the  Human Atherosclerosis  Microarray.  Table  shows  genes  with a  log 2 fold   change 
49 
50 
51 greater or equal to 1.5 upregulation or downregulation, and the related P   value. 
52 
53 
54 
55 
56 
57 
58 
59 
Gene Log 2 fold change 
(treated/control) 
P value (ratio paired t-test) 
Upregulated:  
 
3.46 
 
 
0.12 MMP1 
MMP3 3.08 0.17 
PPARG 2.99 0.22 
IL1R2 2.96 0.19 
ITGB2 1.5 0.33 
Downregulated:  
 
-1.91 
 
 
0.34 IL5 
VWF -2.06 0.41 
BIRC3 -2.62 0.49 
KDR -3.62 0.18 
IL1A -5.32 0.02 
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Figure 4: PDGF - miR-21 axis in SV-SMC 
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